Head-to-head · free

Arbutus Biopharma Corp vs Becton, Dickinson and Company

ABUS vs BDX — return on capital, cash generation, margins and balance sheet side by side.

ABUS

2 / 6

measures where ABUS leads

BDX

4 / 6

measures where BDX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureABUS · FY2025BDX · FY2025
Revenue$14.1M$21.8B
Net income(33.5M)$1.7B
Revenue growth (yearly, multi-year)6.4%1.9%
Free cash flow(39.6M)—
Free cash flow margin-281.5%—
Net cash / (debt)——
ROIC—5.1%
Return on equity-38.5%6.5%
Gross margin—45.4%
Operating margin-192.1%13.7%
Net debt / EBITDA0.48x3.68x

Figures are as reported by each company; latest fiscal year shown.

Where Arbutus Biopharma Corp's cash went (FY2025)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ABUS profile →

Where Becton, Dickinson and Company's cash went (FY2025)

Capital spending
$760.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full BDX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons